HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CL 331002 (glycylcycline)

Also Known As:
glycylcycline; CL 331,002; CL-331,002; CL-331002; N,N-dimethylglycylamido-6-demethyl-6-deoxytetracycline; 2-Naphthacenecarboxamide, 4-(dimethylamino)-N-((dimethylamino)acetyl)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S-(4alpha,4aalpha,5aalpha,12aalpha))-
Networked: 60 relevant articles (7 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Dowzicky, Michael J: 4 articles (03/2007 - 07/2005)
2. Jones, Ronald N: 4 articles (03/2007 - 07/2005)
3. Cui, Hongjuan: 3 articles (09/2021 - 03/2016)
4. Fritsche, Thomas R: 3 articles (07/2005 - 07/2005)
5. Sader, Helio S: 3 articles (07/2005 - 07/2005)
6. Stilwell, Matthew G: 3 articles (07/2005 - 07/2005)
7. Fu, Yulin: 2 articles (01/2022 - 01/2021)
8. Liu, Dejun: 2 articles (01/2022 - 01/2021)
9. Wang, Yang: 2 articles (01/2022 - 01/2021)
10. Zhai, Weishuai: 2 articles (01/2022 - 01/2021)

Related Diseases

1. Infections
2. Intraabdominal Infections
12/01/2008 - "Tigecycline, a new glycylcycline with an expanded broad spectrum of in vitro activity, was recently approved for the treatment of complicated skin and soft tissue infections (cSSTIs) and complicated intra-abdominal infections (cIAIs). "
10/01/2008 - "Tigecycline (TGC), a first-in-class glycylcycline that has been approved for treating complicated skin and skin structure infections and complicated intra-abdominal infections, has an expanded spectrum of activity against Gram-positive, Gram-negative, anaerobic, and atypical bacteria, including resistant strains. "
06/01/2007 - "References were identified through MEDLINE (1966-February 2007) and International Pharmaceutical Abstracts (1970-February 2007) databases, using the key words tigecycline, glycylcycline, complicated skin and skin structure infections (cSSSI), complicated intraabdominal infections (cIAI), and in vitro. "
05/01/2006 - "Therefore, the launch on the American market in June 2005 of tigecycline, a first-in-class glycylcycline indicated in the treatment of complicated skin and skin structure infections and complicated intra-abdominal infections, will provide to physicians a new therapeutic option against hospital or community-acquired resistant pathogens. "
07/01/2005 - "Tigecycline, a novel broad-spectrum parenteral glycylcycline, has been shown to be active against many of Gram-positive, Gram-negative, atypical, and anaerobic organisms, including strains highly resistant to commonly prescribed antimicrobials and was recently approved by the US Food and Drug Administration for treating infections of skin and skin structures, and for intra-abdominal infections. "
3. Pneumonia (Pneumonitis)
4. Endocarditis
5. Legionnaires' Disease (Legionnaire's Disease)

Related Drugs and Biologics

1. Tigecycline (Tygacil)
2. Tetracycline (Achromycin)
3. Anti-Bacterial Agents (Antibiotics)
4. Vancomycin
5. Minocycline (Cyclops)
6. Anti-Infective Agents (Microbicides)
7. Linezolid (Zyvox)
8. Penicillins (Penicillin)
9. Metronidazole (Metric)
10. Clindamycin (Cleocin)